EHA 2018 | Venetoclax monotherapy in patients with R/R MCL

On Saturday 16^th June an oral abstract session took place at the 23^rd Congress of the European Hematology Association (EHA). Abstract S855 was presented by Toby Eyre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, on the efficacy outcomes of venetoclax monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) after therapy with BTK inhibitors.

Study Overview

• This study was retrospective and included centers in the UK and Ireland
• 20 R/R MCL patients were included in the study who were treated with venetoclax between March 2016 and May 2018. Patients were eligible if they had prior lines of therapy and previous exposure to BTK inhibitors
• Patients had a median of 3 lines of prior therapy (range, 2–5) and a median duration of 4.8 months exposure to BTK inhibitor therapy (range, 0.7–34.8)

Key Findings

• Median follow-up was 5.1 months
• The overall response rate was 60% with a complete response of 20% and partial response of 40%
• Median progression-free survival (PFS) was 3.2 months (95% CI, 1.2 – 11.3 months)
• Median overall survival (OS) was 9.4 months (95% CI, 1.5 months – not reached (NR))
• Median duration of response (DOR) was 7.8 months (95% CI, 1.0 months – NR)

Safety

• Grade 4 sepsis occurred in 1 patient, Grade 3 pneumonia occurred in 3 patients, and Grade 2 diarrhoea, fatigue and headache occurred in 2 patients per each adverse event

Dr Eyre provided an overview of the outcomes of this study below: